A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
This is a First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability
and Pharmacokinetics of HH2710 in Patients with Advanced Tumors, composed of a Phase I dose
escalation and dose expansion stage and a Phase II dose extension stage.